The prognostic significance of optimal debulking in the setting of a complete clinical response for advanced ovarian carcinoma patients receiving maintenance chemotherapy

Archives of Gynecology and Obstetrics

Volumn 283, Issue 5, 2011, Pages 1127-1131

  Abaid, Lisa N ^a   Goldstein, Bram H ^a   Lopez, Katrina L ^b   Micha, John P ^a   Brown III, John V ^a   Rettenmaier, Mark A ^a   Markman, Maurie ^c  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b Women's Cancer Research Foundation   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Gynecologic oncology; Maintenance chemotherapy; Ovarian cancer; Surgical debulking

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PACLITAXEL; RETROSPECTIVE STUDIES;

EID: 79956095546     PISSN: 09320067     EISSN: 14320711     Source Type: Journal    
DOI: 10.1007/s00404-010-1571-5     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57:43-66 (Pubitemid 46148091)
2. Sugiyama T, Konishi I (2008) Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs 13:523-536
3. Winter WE III, Maxwell GL, Tian C et al (2008) Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a gynecologic oncology group study. J Clin Oncol 26:83-89
4. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB (2008) Are three additional cycles of chemotherapy useful in patients with advanced-stage epithelial ovarian cancer after a complete response to six cycles of intravenous adjuvant paclitaxel and carboplatin? Jpn J Clin Oncol 38:445-450
5. Wakabayashi MT, Lin PS, Hakim AA (2008) The role of cytoreductive/ debulking surgery in ovarian cancer. J Natl Compr Canc Netw 6:803-810
6. Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY (1999) Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72:278-287 (Pubitemid 29118182)
7. Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Aghajanian C, Barakat RR, Chi DS (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276-281
8. Goldie JH, Coldman AJ (1984) The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Cancer Res 44:3643-3653 (Pubitemid 14041569)
9. Herzog TJ, Coleman RL, Markman M, Cella D, Thigpen JT (2006) The role of maintenance therapy and novel taxanes in ovarian cancer. Gynecol Oncol 102:218-225 (Pubitemid 44041636)
10. Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 21:2460-2465 (Pubitemid 46606325)
11. Lambert HE, Rustin GJ, Gregory WM, Nelstrop AE (1997) A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma North Thames Ovary Group Study. Ann Oncol 8:327-333 (Pubitemid 27230972)
12. Hakes TB, Chalas E, Hoskins WJ et al (1992) Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289
13. Bertelsen K, Jakobsen A, Stroyer J, Nielsen K, Sandberg E, Andersen JE et al (1993) A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group (DACOVA) trial. Gynecol Oncol 49:30-36 (Pubitemid 23148578)
14. Micha JP, Goldstein BH, Graham C et al (2006) Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma. Oncology 71:49-53
15. Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S (2003) Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90:390-396 (Pubitemid 36952033)
16. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 9:1138-1150
17. Rustin GJ, Marples M, Nelstrop AE, Mahmoudi M, Meyer T (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054-4057 (Pubitemid 32976692)
18. Therasse P, Arbuck SG et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
19. Chi DS, Liao JB, Leon LF et al (2001) Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82:532-537 (Pubitemid 32826455)
20. Le T, Krepart GV, Lotocki RJ, Heywood MS (1997) Does debulking surgery improve survival in biologically aggressive ovarian carcinoma? Gynecol Oncol 67:208-214
21. Bristow RE, Montz FJ (2001) Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator. Gynecol Oncol 83:39-48 (Pubitemid 32959877)
22. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6 (Pubitemid 26012496)
23. Ozols RF, Bundy BN, Greer BE, Gynecologic Oncology Group et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200 (Pubitemid 46606249)
24. du Bois A, Luck HJ, Meier W et al (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95:1320-1329